Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.221
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-38753536

RESUMEN

BACKGROUND: Dermatophytoma, also described as a longitudinal streak/spike, is a form of onychomycosis that presents as yellow/white streaks or patches in the subungual space, with dense fungal masses encased in biofilm. This scoping review of the literature was conducted to address a general lack of information about the epidemiology, pathophysiology, and treatment of dermatophytomas in onychomycosis. METHODS: A search was performed in the PubMed and Embase databases for the terms "longitudinal spike" or "dermatophytoma." Outcomes of interest were definition, prevalence, methods used for diagnosis, treatments, and treatment efficacy. Inclusion and exclusion of search results required agreement between two independent reviewers. RESULTS: Of a total of 51 records, 37 were included. Two reports provided the first unique definitions/clinical features of dermatophytomas. Overall, many descriptions were found, but one conclusive definition was lacking. Prevalence data were limited and inconsistent. The most frequently mentioned diagnostic techniques were clinical assessment, potassium hydroxide/microscopy, and fungal culture/mycology. Oral terbinafine and topical efinaconazole 10% were the most frequently mentioned treatments, followed by topical luliconazole 5% and other oral treatments (itraconazole, fluconazole, fosravuconazole). In studies with five or more patients without nail excision, cure rates were highest with efinaconazole 10%, which ranged from 41% to 100% depending on the clinical and/or mycologic assessment evaluated. Other drugs with greater than or equal to 50% cure rates were topical luliconazole 5% (50%), oral fosravuconazole (57%), and oral terbinafine (67%). In studies that combined oral terbinafine treatment with nail excision using surgical or chemical (40% urea) methods, cure rates ranged from 50% to 100%. CONCLUSIONS: There is little published information regarding dermatophytomas in onychomycosis. More clinical research and physician education are needed. Although dermatophytomas have historically been considered difficult to treat, the efficacy data gathered in this scoping review have demonstrated that newer topical treatments are effective, as are oral antifungals in combination with chemical or surgical methods.


Asunto(s)
Antifúngicos , Onicomicosis , Humanos , Onicomicosis/diagnóstico , Onicomicosis/epidemiología , Onicomicosis/terapia , Onicomicosis/tratamiento farmacológico , Antifúngicos/uso terapéutico , Prevalencia , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/terapia , Dermatosis del Pie/epidemiología , Dermatosis del Pie/microbiología , Tiña/diagnóstico , Tiña/terapia , Tiña/epidemiología , Tiña/tratamiento farmacológico , Femenino , Masculino
3.
J Drugs Dermatol ; 23(2): 110-112, 2024 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-38306131

RESUMEN

Good adherence to treatment is necessary for the successful treatment of onychomycosis and requires that an appropriate amount of medication be prescribed. Most prescriptions for efinaconazole 10% solution, a topical azole antifungal, are for 4 mL per month but there are no data on patient factors or disease characteristics that impact how much medication is needed. Data from two phase 3 studies of efinaconazole 10% solution for the treatment of toenail onychomycosis were pooled and analyzed to determine monthly medication usage based on the number of affected toenails, percent involvement of the target toenail, body mass index (BMI), and sex. Participants with two or more affected nails required, on average, >4 mL of efinaconazole per month, with increasing amounts needed based on the number of nails with onychomycosis (mean: 4.39 mL for 2 nails; 6.36 mL for 6 nails). In contrast, usage was not greatly impacted by target toenail involvement, BMI, or sex. Together, these data indicate that the number of affected nails should be the major consideration when determining the monthly efinaconazole quantity to prescribe. J Drugs Dermatol. 2024;23(2):110-112.    doi:10.36849/JDD.7676.


Asunto(s)
Dermatosis del Pie , Onicomicosis , Humanos , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Onicomicosis/microbiología , Uñas , Administración Tópica , Triazoles/uso terapéutico , Antifúngicos , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/tratamiento farmacológico , Dermatosis del Pie/microbiología
5.
J Drugs Dermatol ; 22(10): 1017-1020, 2023 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-37801521

RESUMEN

Recently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results.  Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomycosis. Sixty patients with onychomycosis of Fitzpatrick skin types IV to VI, between 15 and 65 years of age, were divided into a continuous treatment group receiving 250 mg terbinafine once daily for 12 weeks and a pulse treatment group receiving 250 mg twice daily terbinafine for 1 week repeated every 4 weeks for 12 weeks. Each patient was followed up at weeks 4, 8, and 12.  Efficacy of the continuous treatment group was significantly greater at 76.67% compared with 26.67% in the pulse treatment group. Thus, we conclude that the clinical cure rate of a continuous dose regimen of terbinafine is a superior treatment option for toenail onychomycosis. However, we also suggest further studies including combinations of multiple agents and hybrid regimen models for the optimal onychomycosis treatment.   J Drugs Dermatol. 2023;22(10):     doi:10.36849/JDD.7323R1.


Asunto(s)
Dermatosis del Pie , Onicomicosis , Humanos , Terbinafina/uso terapéutico , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Naftalenos/uso terapéutico , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/tratamiento farmacológico , Antifúngicos , Itraconazol/efectos adversos , Resultado del Tratamiento
8.
Int J Dermatol ; 61(11): 1385-1389, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35535809

RESUMEN

BACKGROUND: Increased detection of fungi including non-dermatophyte molds (NDMs) using polymerase chain reaction (PCR) methods is well-established. However, the use of PCR to evaluate ongoing onychomycosis treatment outcome has not been investigated. METHODS: Nail samples from 28 patients receiving topical efinaconazole were evaluated by both KOH/culture and PCR methods across the study period. Detection of microorganisms by PCR was compared to the culture at baseline and end of study at month 24 (M24). Fungal detection by both methods was evaluated with respect to clinical cure observed as 100% visual clearance of the target toenail. RESULTS: By culture, all 28 subjects were dermatophyte-positive at pre-treatment; only 4/28 also exhibited an NDM microorganism. According to PCR, 24/28 subjects were dermatophyte-positive pre-treatment, with 25/28 also exhibiting NDMs. At M24, 18/28 (64.3%) participants had negative KOH/culture results, in contrast to 4/28 (14.3%) negative PCR results. PCR showed higher rates of NDM detection than the culture at baseline as well as M24. Calculations to compare the diagnostic utility of KOH/culture versus PCR found that positive tests with both methods reliably indicate the presence of onychomycosis, but negative PCR correlated better with onychomycosis cure than did KOH/culture. DISCUSSION: PCR confirmed a high presence of NDMs pre-treatment, and continued presence of NDMs to M24, with unknown significance requiring further investigation. Though both KOH/culture and PCR have diagnostic limitations, PCR showed better overall utility than culture in predicting onychomycosis topical treatment outcome and should be more strongly considered for evaluation of topical therapies.


Asunto(s)
Dermatosis del Pie , Onicomicosis , Administración Tópica , Antifúngicos/uso terapéutico , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/tratamiento farmacológico , Dermatosis del Pie/microbiología , Hongos , Humanos , Uñas , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Onicomicosis/microbiología , Reacción en Cadena de la Polimerasa
9.
J Cutan Pathol ; 49(7): 632-637, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35148432

RESUMEN

Papular-purpuric "gloves and socks" syndrome (PPGSS) is a unique, self-limited dermatosis characterized by edema, erythema, and pruritic petechiae and papules in a distinct "gloves and socks" distribution. This is often accompanied by systemic symptoms, including fever, lymphadenopathy, asthenia, myalgia, and arthralgias. PPGSS has also been described as a manifestation of an underlying immunological mechanism that can be triggered by viral or drug-related antigens. A 32-year-old male developed a painful eruption on the bilateral hands and feet after being diagnosed with influenza B. On examination, scattered papular purpura with occasional overlying scale was noted on the bilateral hands, fingers, feet, toes, volar wrists, and ankles. Histopathologic sections showed a mixed pattern of inflammation with interface and spongiotic changes. A parakeratotic scale with overlying basket-weave orthokeratosis was also seen. Within the epidermis, there was intraepidermal vesicles and Langerhans cell microabscess formation with scattered apoptotic keratinocytes. The underlying dermis showed a superficial perivascular lymphocytic infiltrate with mild edematous changes, and extravasation of red blood cells. Clinicopathologic correlation strongly supported a diagnosis of popular-purpuric gloves and socks syndrome. The influenza virus has never been reported in association with PPGSS; thus, this case outlines an important new variant that clinicians should be familiar with.


Asunto(s)
Dermatosis del Pie , Dermatosis de la Mano , Gripe Humana , Parvovirus B19 Humano , Púrpura , Adulto , Edema , Dermatosis del Pie/diagnóstico , Humanos , Masculino , Púrpura/diagnóstico
11.
Dermatitis ; 33(1): 62-69, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35029350

RESUMEN

BACKGROUND: Shoe contact allergy can be difficult to diagnose and manage. OBJECTIVE: The aim of the study was to characterize demographics, clinical characteristics, patch test results, and occupational data for the North American Contact Dermatitis Group patients with shoe contact allergy. METHODS: This is a retrospective study of 33,661 patients, patch tested from 2005 to 2018, with a shoe source, foot as 1 of 3 sites of dermatitis, and final primary diagnosis of allergic contact dermatitis. RESULTS: Three hundred fifty-two patients met the inclusion criteria. They were more likely to be male (odds ratio = 3.36, confidence interval = 2.71-4.17) and less likely to be older than 40 years (odds ratio = 0.49, confidence interval = 0.40-0.61) compared with others with positive patch test reactions. The most common relevant North American Contact Dermatitis Group screening allergens were potassium dichromate (29.8%), p-tert-butylphenol formaldehyde resin (20.1%), thiuram mix (13.3%), mixed dialkyl thioureas (12.6%), and carba mix (12%). A total of 29.8% (105/352) had positive patch test reactions to supplemental allergens, and 12.2% (43/352) only had reactions to supplemental allergens. CONCLUSIONS: Shoe contact allergy was more common in younger and male patients. Potassium dichromate and p-tert-butylphenol formaldehyde resin were the top shoe allergens. Testing supplemental allergens, personal care products, and shoe components should be part of a comprehensive evaluation of suspected shoe contact allergy.


Asunto(s)
Alérgenos/efectos adversos , Dermatitis Alérgica por Contacto/diagnóstico , Dermatosis del Pie/diagnóstico , Zapatos/efectos adversos , Adulto , Colorantes/efectos adversos , Estudios Transversales , Dermatitis Alérgica por Contacto/etiología , Femenino , Dermatosis del Pie/etiología , Humanos , Masculino , Persona de Mediana Edad , América del Norte , Pruebas del Parche/métodos , Resinas Sintéticas/efectos adversos , Estudios Retrospectivos , Goma/efectos adversos , Adulto Joven
13.
Clin Exp Dermatol ; 47(2): 399-403, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34411313

RESUMEN

BACKGROUND: Acute pseudoperniosis (PP) has a recognized association with COVID-19 and tends to occur without cold precipitation in young, healthy patients, often without a clear history of COVID-19. These lesions usually resolve within 2 weeks and without long-term sequelae. In the early months of 2021, patients with delayed and protracted PP began to emerge. We have called this presentation 'tardive COVID-19 PP (TCPP)'. AIM: To consolidate and expand knowledge on TCPP, we describe the clinical characteristics, treatments and outcomes of 16 patients with TCPP who were reviewed by our outpatient dermatology service. RESULTS: The initial clinical manifestations were erythema, swelling and PP of the fingers in 56.2%, and of the toes in 31.2%, desquamation in 56.2% and acrocyanosis in 12.5%. Ten patients had eventual involvement of all acral sites. The median duration of symptoms was 191 days. Six patients reported close contact with a confirmed or suspected case of COVID-19, but only two had positive COVID-19 tests. Four patients experienced complete or almost complete resolution of symptoms, while the rest remain under active treatment. CONCLUSION: Unlike acute PP, TCPP has a protracted and delayed presentation that is typically associated with profound acrocyanosis. Patients with TCPP represent a new phenomenon that is part of the post-COVID-19 syndrome, with risk factors and pathophysiology that are not yet fully understood. Our data indicate that likely predisposing factors for developing TCPP include young age, a preceding history of cold intolerance and an arachnodactyloid phenotype. Anorexia, connective tissue disorders or sickle cell trait may also predispose to TCPP. In addition, low titre antinuclear antibody positivity, the presence of cryoglobulins, or low complement levels may represent further risk factors. Finally, prolonged low temperatures are also likely to be contributing to the symptoms.


Asunto(s)
COVID-19/complicaciones , Eritema Pernio/diagnóstico , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/virología , Dermatosis de la Mano/diagnóstico , Dermatosis de la Mano/virología , Enfermedad Aguda , Adolescente , Adulto , Anciano , COVID-19/diagnóstico , COVID-19/terapia , Eritema Pernio/terapia , Eritema Pernio/virología , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Adulto Joven , Síndrome Post Agudo de COVID-19
14.
Clin Exp Dermatol ; 47(3): 593-594, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34700361

RESUMEN

Cutaneous larva migrans acquired in western Scotland. A reminder that with a warming climate, conditions conventionally restricted to the tropics may be contracted in the British Isles in the absence of foreign travel.


Asunto(s)
Dermatosis del Pie/diagnóstico , Larva Migrans/diagnóstico , Enfermedad Relacionada con los Viajes , Adulto , Albendazol/uso terapéutico , Antinematodos/uso terapéutico , Femenino , Dermatosis del Pie/tratamiento farmacológico , Dermatosis del Pie/patología , Humanos , Larva Migrans/tratamiento farmacológico , Larva Migrans/patología , Escocia
15.
Clin Exp Dermatol ; 47(1): 63-71, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34236713

RESUMEN

BACKGROUND: Palmoplantar pustulosis (PPP) is a rare, chronic, inflammatory skin disease characterized by sterile pustules on palmar or plantar areas. Data on PPP are scarce. AIM: To investigate the clinical characteristics and risk factors for disease severity in a large cohort of Turkish patients with PPP. METHODS: We conducted a cross-sectional, multicentre study of patients with PPP recruited from 21 tertiary centres across Turkey. RESULTS: In total, 263 patients (165 women, 98 men) were evaluated. Most patients (75.6%) were former or current smokers. The mean Palmoplantar Pustulosis Area and Severity Index (PPPASI) was 8.70 ± 8.06 and the mean Dermatology Life Quality Index (DLQI) score was 6.87 ± 6.08, and these scores were significantly correlated (r = 0.52, P < 0.001). Regression analysis showed that current smoking was significantly associated with increased PPPASI (P = 0.03). Coexisting psoriasis vulgaris (PsV) was reported by 70 (26.6%) patients. Male sex prevalence, PPP onset incidence, disease duration, DLQI, and prevalence of nail involvement and psoriatic arthritis (PsA) were significantly increased among patients with PPP with PsV. Of the 263 patients, 18 (6.8%) had paradoxical PPP induced by biologic therapy, and these patients had significantly increased mean DLQI and prevalence of PsA (r = 0.03, P = 0.001). CONCLUSION: Our data suggest that smoking is a risk factor for both PPP development and disease severity. Patients with PPP with PsV present distinct clinical features and patients with biologic therapy-induced paradoxical PPP have reduced quality of life and are more likely to have PsA.


Asunto(s)
Dermatosis del Pie/diagnóstico , Dermatosis del Pie/epidemiología , Dermatosis de la Mano/diagnóstico , Dermatosis de la Mano/epidemiología , Psoriasis/diagnóstico , Psoriasis/epidemiología , Calidad de Vida , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Turquía/epidemiología
16.
J Drugs Dermatol ; 20(10): 1076-1084, 2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34636509

RESUMEN

BACKGROUND: Onychomycosis affects around 14% of individuals in North America and Europe and is undertreated. Treatment is challenging as toenail growth can take 12–18 months, the nail plate may prevent drug penetration, and disease recurrence is common. National guidelines/consensus documents on onychomycosis diagnosis and treatment were last published more than 5 years ago and updated medical guidance is needed. METHODS: This document aims to provide recommendations for the diagnosis and pharmaceutical treatment of toenail onychomycosis following a roundtable discussion with a panel of dermatologists, podiatrists, and a microbiologist specializing in nail disease. RESULTS: There was a general consensus on several topics regarding onychomycosis diagnosis, confirmatory laboratory testing, and medications. Onychomycosis should be assessed clinically and confirmed with microscopy, histology, and/or culture. Terbinafine is the primary choice for oral treatment and efinaconazole 10% for topical treatment. Efinaconazole can also be considered for off-label use for maintenance to prevent recurrences. For optimal outcomes, patients should be counseled regarding treatment expectations as well as follow-up care and maintenance post-treatment. CONCLUSIONS: This article provides important updates to previous guidelines/consensus documents to assist dermatologists and podiatrists in the diagnosis and treatment of toenail onychomycosis. J Drugs Dermatol. 2021;20(10):1076-1084. doi:10.36849/JDD.6291.


Asunto(s)
Dermatosis del Pie , Enfermedades de la Uña , Onicomicosis , Administración Tópica , Antifúngicos/uso terapéutico , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/tratamiento farmacológico , Humanos , Enfermedades de la Uña/tratamiento farmacológico , Uñas , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Terbinafina/uso terapéutico , Resultado del Tratamiento
17.
Clin Podiatr Med Surg ; 38(4): 561-568, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34538434

RESUMEN

Shoe dermatitis is a type of contact dermatitis precipitated by allergens or irritants found in shoes. Potassium dichromate, commonly used in leather processing, is one of the most prevalent agents responsible for shoe dermatitis; however, it is not the only one. Shoe dermatitis caused by an allergen or an irritant may affect a person of any age, sex, or ethnicity. Numerous treatments exist for shoe dermatitis, the most simple yet important being avoidance of causative agents. Pharmaceutical agents commonly used are emollients, humectants, and topical corticosteroids. In more severe cases, topical calcineurin inhibitors and phototherapy may be used.


Asunto(s)
Dermatitis Alérgica por Contacto , Dermatosis del Pie , Alérgenos , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/etiología , Dermatosis del Pie/terapia , Humanos , Pruebas del Parche , Zapatos
19.
Bol. micol. (Valparaiso En linea) ; 36(1): 17-24, jun. 2021. ilus, tab
Artículo en Español | LILACS | ID: biblio-1381658

RESUMEN

La prevalencia global de la onicomicosis pedis es de 4,3%, y en hospitalizados puede llegar hasta 8,9%. Aun así, se propone que está ampliamente subdiagnosticada. Personas añosas con comorbilidades presentan mayor riesgo de onicomicosis pedis y de sus complicaciones. Se examinaron aleatoriamente a 64 pacientes hospitalizados en el Servicio de Medicina del Hospital San José. A aquellos con signos clínicos de onicomicosis pedis se les realizó un examen micológico directo (MD) y estudio histopatológico de un corte de uña teñido con PAS (Bp/PAS). Muestra de 64 pacientes, un 78,1% presentó onicomicosis pedis clínica y en un 70,3% se confirmó el diagnóstico con MD y/o Bp/PAS positivo. De los pacientes con onicomicosis confirmada, el promedio de edad fue de 67,8 +/- 12,3 años. Un 44% correspondió al sexo femenino y un 56% al sexo masculino. La onicomicosis pedis en el servicio de medicina interna del Hospital San José es una condición frecuente. El conjunto de MD y Bp/PAS podría ser considerado como una buena alternativa diagnóstica. (AU)


Onychomycosis of the toenails has a global prevalence of 4,3% and can reach up to 8,9% in hospitalized patients. It has been hypothesized that it is widely under diagnosed. Aged patients with multiple diseases have an increased risk of Onychomycosis and its complications. 64 patients of the internal medicine ward were randomly selected. Those who had clinical signs of onychomycosis of the toenails were tested with direct microscopy and histological study of the nail plate with PAS staining. Of the 64 patients, 78,1% (50) had clinical signs of onychomycosis of the toenails and in 70,3% (45) the diagnosis was confirmed either by direct microscopy and/or by histological study of the nail plate with PAS staining. The mean age for the group with onychomycosis was 67,8 +/- 12,3 ages. 44% were female and 56% were male. Onychomycosis of the toenails is a frequent condition at the internal medicine ward of the San José Hospital. The direct microscopy together with the histological study of the nail plate with PAS staining seem to be a good diagnosis alternative. (AU)


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Onicomicosis/epidemiología , Centros de Atención Terciaria/estadística & datos numéricos , Dermatosis del Pie/epidemiología , Chile/epidemiología , Prevalencia , Onicomicosis/diagnóstico , Onicomicosis/microbiología , Onicomicosis/patología , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/microbiología , Dermatosis del Pie/patología , Hospitalización/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA